Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7460700 | 0.99 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6179255 | 0.81 | CHRM2 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL6180475 | 0.81 | L3MBTL1 (0.50) | CA12CA1CA2CA4SCN8A | |
| SCHEMBL4605920 | 0.81 | GAA (0.53) | KDM4EALDH1A1BCHE | |
| SCHEMBL2787662 | 0.77 | HRH3 (0.49) | LOXL2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL17654953 | 0.77 | EPHX2 (0.33) | KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL31364603 | 0.75 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31364605 | 0.75 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL29912750 | 0.75 | LOXL2 (0.65) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7961162 | 0.74 | TBXAS1 (0.44) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973882-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1140909-B1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040087592-A1 | Treatment of malaria with farnesyl protein transferase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-06 | — | — | US | disclosed |
| US-6645966-B2 | Reverse malaria drug resistance | SCHERING CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030134846-A1 | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-20030092705-A1 | Treatment of malaria with farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
| WO-2002080895-A2 | TREATMENT OF MALARIA WITH FARSENYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6432959-B1 | ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-08-13 | — | — | US | disclosed |
| WO-2002056884-A2 | TREATMENT OF MALARIA WITH FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| EP-0935464-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5925651-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5922883-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999018096-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0891335-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997036584-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036877-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134846-A1 | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors | FNTB, FNTA, SOAT1 | CA12 4587/4885CA1 4644/4885CA2 4428/4885 |
| US-20040087592-A1 | Treatment of malaria with farnesyl protein transferase inhibitors | FNTA, FNTB, SOAT1 | CA12 4656/4885CA1 4650/4885CA2 4318/4885 |
| US-20030092705-A1 | Treatment of malaria with farnesyl protein transferase inhibitors | FNTA, FNTB, SOAT1 | CA12 4656/4885CA1 4650/4885CA2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.